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Abstracts 
DNA methylation in the promoter region of a gene is associated with a loss of that 
gene’s expression and plays an important role in gene silencing.  The inactivation of 
tumor-suppressor genes by aberrant methylation in the promoter region is well 
recognized in carcinogenesis (Baylin et al., 1997; Ushijima 2005). However, there has 
been little study in this area when it comes to genome-wide profiling of the promoter 
methylation.  Here we developed a genome-wide profiling method called 
Microarray-based Integrated Analysis of Methylation by Isoschizomers (MIAMI) to 
analyze the DNA methylation of promoter regions of 8,091 human genes.  With this 
method, resistance to both the methylation-sensitive restriction enzyme Hpa II and the 
methylation-insensitive isoschizomer Msp I was compared between samples by using a 
microarray with promoter regions of the 8,091 genes.  The reliability of the difference 
in Hpa II resistance was judged using the difference in Msp I resistance.   We 
demonstrated the utility of this method by finding epigenetic mutations in cancer.  
Aberrant hypermethylation is known to inactivate tumour suppressor genes. Using this 
method, we found that frequency of the aberrant promoter hypermethylation in cancer is 
higher than previously hypothesized. Aberrant hypomethylation is known to induce 
activation of oncogenes in cancer.  Genome-wide analysis of hypomethylated promoter 
sequences in cancer demonstrated low CG/GC ratio of these sequences, suggesting that 
CpG-poor genes are sensitive to demethylation activity in cancer. 
 
Text 
Microarray-based methods of comparing differences in DNA methylation in 
the genome of two samples using methylation-sensitive restriction enzymes (Yan et al., 
2001; Hatada et al., 2002)  have two problems.  The first is that the microarrays 
contain clones from libraries of CpG islands. CpG islands are CpG-rich regions of the 
genome originally thought to be associated with the 5’ region of genes.  There were 
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several approaches using CpG islands libraries for microarrays (Yan et al., 2001; Hatada 
et al., 2002; Heisler et al. 2005; Weber et al.).  Although 60% of human genes have 
CpG islands in the promoter or first exon, more than 80% of all CpG islands have no 
relation to genes and are unlikely to regulate gene expression (Takai and Jones; 2002).  
To solve this problem, we used a microarray with 60-mer oligonucleotides derived from 
promoter regions of 8,091 human genes.  DNA methylation in promoter regions is 
most important for the regulation of gene expression.  The second problem is the risk 
of false positives resulting from restriction site polymorphisms and/or incomplete 
digestion of DNA.  To resolve this issue, we developed a new method called 
Microarray-based Integrated Analysis of Methylation by Isoschizomers (MIAMI). We 
utilized resistance to a methylation-insensitive restriction enzyme, Msp I, to judge the 
false positive results for resistance to the methylation-sensitive isoschizomer Hpa II 
(Fig.1a).  If two samples have a restriction site polymorphism at a Hpa II site and/or  
one of the samples has incomplete digestion at a Hpa II site, they will differ in 
resistance to Hpa II.  However, in this case the resistance to methylation-insensitive 
Msp I at this site will also differ between samples because both enzymes recognize the 
same recognition site, CCGG.  Therefore, we can treat such changes as false positives 
based on Msp I resistance. 
We constructed a 60-mer-oligonucleoide microarray containing portions of 
Hpa II fragments located in promoter regions of 8,091 genes.  We targeted the region 
from 600 base pairs upstream to 200 base pairs downstream of the transcriptional start 
sites for genes whose start sites were characterized on the basis of the National Center 
for Biotechnology Information (NCBI) annotation and/or Database of Transcriptional 
Start Sites (DBTSS).  The probe nearest to a transcriptional start was selected on the 
condition that it doesn’t have self complementarity (Primer 3 program, Rozen et al., 
2000) and homology to the human genome (megaBlast program, Altschul et al., 1990). 
Microarrays were made using an ink-jet oligonucleotide synthesizer as described 
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(Hughes et al., 2001).  Average position of the 8,091 probes was 36 base pairs 
upstream of the transcription start sites.   Average GC content of the probes was 65%.  
All probes were included in the Hpa II fragments less than 600 base pairs.  Average 
fragment length of the probe containing Hpa II fragments was 194 base pairs.     
We defined resistance as reciprocal of sensitivity.  Therefore, Hpa 
II-sensitive (cleavable) DNA and Msp I-sensitive (cleavable) DNA were amplified and 
used for calculating the Hpa II resistance and Msp I resistance, respectively.  For Hpa 
II resistance, Hpa II-cleavable unmethylated DNA was amplified (I). Hpa II-cleaved 
DNA fragments were ligated to an adaptor and subjected to first PCR (Fig.1a).  At this 
stage, only DNA fragments which had methylated internal Hpa II sites before the PCR 
retained Hpa II (Msp I) sites.  Therefore, Msp I digestion made it impossible to 
amplify these methylated fragments.  In the second main PCR, only unmethylated 
DNA fragments were amplified. Amplified unmethylated Hpa II-cleaved DNA 
fragments from two samples were labeled with Cy3 and Cy5, respectively, and 
cohybridized to the microarray with 60-mer oligonucleotides from promoter regions of 
8,091 genes.  After hybridization, the microarray was scanned and fluorescence 
intensities on a scanned image were quantified, corrected for background noise, and 
normalized with the software DNASIS Array (Hitachi Software Engineering).  Spots 
with both Cy3 and Cy5 signals less than 0.001% of total signals  were removed before 
analysis. Hpa II resistance (HR) was defined as 1/(normalized Hpa II intensity).  
Therefore, the ratio of Hpa II resistance of two samples (HRB/HRA) can be represented 
by (normalized Hpa II intensity)A/(normalized Hpa II intensity)B. For Msp I resistance, 
all Msp I -cleavable DNA (unmethylated plus methylated) was amplified (II). Msp 
I-cleaved DNA fragments were amplified and labeled the same as Hpa II-cleaved DNA 
fragments then cohybridized to another microarray with the same 8,091 genes.  Msp I 
resistance (MR) was defined as 1/(normalized Msp I intensity).  Therefore, the ratio of 
Msp I resistance of two samples (MRB/MRA) can be represented by (normalized Msp I 
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intensity)A/(normalized Msp I intensity)B.  Details for all procedures are described in 
Supplementary information 1. 
We applied the MIAMI method to a lung cancer cell line (1-87, abbreviated as 
LC) and a normal lung (abbreviated as C).  Values for log(HRLC/HRC) and 
log(MRLC/MRC) are plotted on the x and the y-axis, respectively, of Fig. 1b.  Various 
genes whose Hpa II resistance (HR) changed more than 5-fold ( abs[log(HRLC/HRC)] > 
log5, areas more than log5 of the horizontal distance from the y axis) were selected as 
candidates (indicated by red and green circles in Fig. 1b and Supplementary Fig. 1).  
These genes were confirmed to differ in methylation between the cancer and the normal 
lung by combined bisulfite restriction (COBRA) analysis, with the genes indicated by 
red circles hypermethylated in the cancer cells and the genes indicated by green circles 
having no methylation-based changes (Fig. 2a).  To characterize these false positives 
without changes in methylation (green circles), PCR was conducted followed by 
digestion with Hpa II to test for site polymorphisms.  We found these false positives 
have site polymorphisms between the cancer and the normal lung (Fig. 2b).  All these 
false positives were close to the regression line (yellow line in Fig. 1b and 
Supplementary Fig. 1) where ideal changes in Hpa II resistance and Msp I resistance are 
postulated to be equal.  Therefore, we made threshold criteria with which to judge 
points located more than log5 of the horizontal distance from the regression line as 
altered genes. (Fig. 1b and Supplementary Fig. 1).  Points located more than this 
distance right of the regression line were judged as hypermethylated and points located 
more than this distance left of the regression line were judged as hypomethylated.  
Using our criteria, we could neglect all false positives (green circles) and all genes 
meeting the criteria (red circles) had methylation changes, indicating our threshold is 
quite reasonable for selecting methylation-changed genes.  Next we chose six genes 
which were located more than log5 of the horizontal distance from the regression line 
but less than log5 from the y-axis (indicated by orange and blue circles in Fig. 1b and 
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Supplementary Fig. 1).  These genes can be judged as hypermethylated using our 
criteria but their changes in Hpa II resistance (HR) are less than 5-fold.  COBRA 
analysis indicated that five of the six had actually methylation-based changes (Fig. 2a), 
indicating again our threshold criteria is useful for selecting methylation-changed genes 
(orange circles indicate positives and blue circles indicates false positive).  
Conventional, independent COBRA experiments using gene-specific primers confirmed 
17 of 18 hypermethylations that were identified by integrated analysis of Hpa II 
resistance and Msp I resistance at a threshold of log5.  This suggests that our empirical 
rate of false positives is 6%.  We used our threshold criteria to calculate the ratio of 
changes and found that 5.7% of the promoters of the genes were hypermethylated and 
0.6% were hypomethylated in lung cancer (Fig. 1c and Supplementary information 2).  
This frequency is much higher than a previous result in lung cancers (Yan et al., 2001), 
suggesting high sensitivity.  Further improvement such as using linear amplification 
could make this method more efficient because it is expected that a proportion of 
fragments will not amplify and give no signal by PCR.  Actually we removed 14% of 
spots with both Cy3 and Cy5 signals less than 0.001% of total signals for analysis to get 
reproducible results. 
Next we analyzed the character of 5’ sequences (from 1000 base pairs 
upstream to 200 base pairs downstream of the transcriptional start sites) for these 
hypermethylated and hypomethylated genes.  Average ratio of CpG contents to GC 
contents (CG/GC) were calculated for hypermethylated, unchanged, and 
hypomethylated genes (Fig. 1d).  We found hypomethylated genes had a low CG/GC 
ratio compared to genes without methylation change (P=4.0 x 10-15, Fig. 1d).  However, 
the AT/TA ratio showed no such tendency (Fig. 1d).  This suggests that CpG-poor 
genes are easily demethylated compared to CpG-rich genes.  In other words, CpG-poor 
genes are more sensitive to demethylation activity than to CpG-rich genes.  This could 
be explained by protection of demethylation activity by a methyl-CpG binding protein.  
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Promoters with a low density of methyl-CpGs bind MeCP-1 less strongly than those 
with a high density of methyl-CpGs (Boyes and Bird, 1992).  Therefore, it is intriguing 
to speculate that CpG-poor genes are less protected by MeCP-1 from demethylation 
activity.  Aberrant hypomethylation is related to the activation of oncogenes.  
Therefore, our finding of the unique character of hypomethylated genes will help us to 
understand the mechanism of carcinogenesis. 
Aberrant hypermethylation is known to inactivate tumour suppressor genes. 
Among the hypermethylated genes we identified, further analysis of CIDEB and MLH3 
were performed. CIDEB, Cell death-inducing DFFA-like effector b, activates apoptosis 
in mammalian cells (Inohara et al., 1998) and is located at 14q11 where LOH frequently 
occurrs in lung cancers (Abujiang et al., 1998).  MLH3, MutL Homolog 3, is a DNA 
mismatch repair gene associated with mammalian microsatellite instability (Lipkin et al., 
2000).  MLH1, from the same family, was frequently mutated in hereditary 
nonpolyposis colon cancer (Papadopoulos et al., 1994) and was involved in 
microsatellite instability DNA in colon cancers (Jager et al., 1997).  A 
methylation-based analysis of an additional five lung cancer cell lines using COBRA 
revealed hypermethylation in five of six for CIDEB and two of six for MLH3 (Fig. 2c).  
RT-PCR analysis showed that expression was reduced in all hypermethylated cancers 
(Fig. 2c), indicating that the expression profile of the genes completely correlated with 
the methylation profile of the genes.  Further methylation analysis were performed for 
CIDEB in primary tumours using COBRA.  We found 71% (15/21) of primary lung 
cancers were hypermethylated in the promoter of CIDEB (Fig. 2d). 
In conclusion, we conclude MIAMI is a powerful method for genome-wide 
profiling of promoter methylation in the human genome.  This method is useful for 
epigenetic studies of cancers. 
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Legends to figures 
 
Fig. 1 Microarray-based Integrated Analysis of Methylation by Isoschizomers (MIAMI). 
(a) Schematic flowchart for the MIAMI method for comparison of sample A and sample 
B.  Details were described in the text.  (b) Application of the MIAMI method to a 
lung cancer cell line (1-87, abbreviated as LC) and a normal lung (abbreviated as C).  
Values for log(HRLC/HRC) are plotted on the x-axis and log(MRLC/MRC) are plotted on 
the y-axis.  Green lines are located log5 of the horizontal distance from the y-axis.  
The regression line is in yellow and red lines are located log5 of the horizontal distance 
from this line.  Points located more than this distance right of the regression line are 
judged as hypermethylated.  Points located more than log5 of the horizontal distance 
left of the regression line are judged as hypomethylated.  Genes indicated by red and 
green circles are located more than this distance from the y-axis.  Hypermethylation 
was confirmed for genes indicated by red circles which were found to meet the criteria.  
Hypermethylation was not confirmed for genes indicated by green circles which did not 
meet the criteria although they were located log5 of the horizontal distance from the 
y-axis.  Orange and blue circles meet the criteria but are less than log5 of the distance 
from the y-axis.  Hypermethylation was confirmed for genes indicated by orange 
circles but not blue circles.  (c) Summary of methylation changes in a lung cancer cell 
line (1-87, abbreviated as LC) compared to a normal lung (abbreviated as C). 
Methylation change (horizontal distance from the regression line) for each gene is 
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plotted on the y-axis. Red broken lines indicate threshold we used (log5). Genes are 
placed in order of position along X-axis. (d) Average ratio of CpG contents to GC 
contents (CG/GC) and average ratio of AT contents to TA contents  (AT/TA) were 
calculated for hypermethylated, unchanged, and hypomethylated genes. 
 
Fig. 2 Characterization of genes detected by MIAMI in a lung cancer. The PCR primers 
used are indicated in Supplementary information 3.  (a) COBRA analysis of indicated 
genes.  Genes indicated by red, orange, and blue circles met our criteria whereas 
indicated by green circles did not.  COBRA analysis confirmed hypermethylation for 
genes indicated in red and orange and not genes indicated by green and blue.  U 
indicates bands originating from unmethylated DNA.  Oher bands originated from 
methylated DNA.  (b) Characterization of genes not meeting our criteria.  Msp I (Hpa 
II) polymorphisms were detected by PCR followed by digestion with Msp I.  All the 
genes not meeting the  criteria have Msp I (Hpa II) polymorphisms.  (c) COBRA and 
RT-PCR analysis of CIDEB and MLH3 genes in 6 lung cancer cell lines (1-87, 
RERF-LCMS, EBC-1, LK-2, VMRC-LCP, and LK79).  U indicates bands originating 
from unmethylated DNA.  Hypermethylation was observed for five of six lung cancer 
cell lines for CIDEB and two of six for MLH3.  RT-PCR analysis showed that 
expression was reduced in all these hypermethylated cell lines.  G3PDH was used for a 
control.   (d) COBRA analysis of CIDEB genes in primary tumours. Eight 
adenocarcinomas, eight squamous cell carcinomas, and five small cell carcinomas were 
used for analysis.  71% (15/21) of primary tumours were hypermethylated.  The 
present study was approved by the Ethics Committees of Tohoku University School of 
Medicine and Gunma University.  Following a complete description of the research 
protocol, written informed consent was obtained from each participant.  
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